WO2025109540 - MACROCYCLIC COMPOUNDS AS KIF18A INHIBITORS
National phase entry:
Publication Number
WO/2025/109540
Publication Date
30.05.2025
International Application No.
PCT/IB2024/061718
International Filing Date
22.11.2024
Title **
[English]
MACROCYCLIC COMPOUNDS AS KIF18A INHIBITORS
[French]
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KIF18A
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
ABBINENI, Chandrasekhar
KADAM, Vijay
SENGUPTA, Sandip
SAMAJDAR, Susanta
SIMONOVICH, Scott
GILLESPIE, Paul
M. GREEN, Evan
SANDERS, John
Priority Data
202341079320
22.11.2023
IN
202441072285
25.09.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4399 | |
| EPO | Filing, Examination, Granting | 27523 | |
| Japan | Filing, Examination, Granting | 2958 | |
| South Korea | Filing, Examination, Granting | 3739 | |
| USA | Filing, Examination, Granting | 12090 |
Total:
50,709
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides macrocyclic compounds of formula (I), which are therapeutically useful as KIF18A inhibitors.(I) These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the inhibition of KIF18A activity. Compounds of the present disclosure are especially useful for treating cancer. The present disclosure also provides processes for the preparation of compounds of formula (I), as well as pharmaceutical formulations comprising at least one compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.[French]
La présente invention concerne des composés macrocycliques de formule (I), qui sont thérapeutiquement utiles en tant qu'inhibiteurs de KIF18A. (I) Ces composés sont utiles dans le traitement et/ou la prévention de maladies et/ou de troubles sensibles à l'inhibition de l'activité de KIF18A. Les composés de la présente divulgation sont particulièrement utiles pour le traitement du cancer. La présente divulgation concerne également des procédés de préparation de composés de formule (I), ainsi que des formulations pharmaceutiques comprenant au moins un composé de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère de celui-ci.